Test results in hand, Thrive raises $257M to push liquid biopsy toward approval
Three months after announcing the results of a landmark trial, Thrive Earlier Detection has raised $257 million to put their liquid biopsy cancer test into a pivotal trial.
Thrive started raising for the Series B immediately after the study results were published in Science at the end of April. That study, run across 10,000 women at the Geisinger Health System, showed for the first time that a blood test could help doctors diagnose certain types of cancer in patients who did not yet show symptoms, more than doubling the percentage of cancers that were detected.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.